Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleEndocrine and Diabetes

TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats

Yoshiyuki Tsujihata, Ryo Ito, Masami Suzuki, Ayako Harada, Nobuyuki Negoro, Tsuneo Yasuma, Yu Momose and Koji Takeuchi
Journal of Pharmacology and Experimental Therapeutics October 2011, 339 (1) 228-237; DOI: https://doi.org/10.1124/jpet.111.183772
Yoshiyuki Tsujihata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryo Ito
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masami Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayako Harada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nobuyuki Negoro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsuneo Yasuma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Momose
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koji Takeuchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 339 no. 1 228-237
DOI 
https://doi.org/10.1124/jpet.111.183772
PubMed 
21752941

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received May 18, 2011
  • Accepted July 12, 2011
  • Published online September 19, 2011.

Article Versions

  • Earlier version (July 13, 2011 - 07:54).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Yoshiyuki Tsujihata,
  2. Ryo Ito,
  3. Masami Suzuki,
  4. Ayako Harada,
  5. Nobuyuki Negoro,
  6. Tsuneo Yasuma,
  7. Yu Momose and
  8. Koji Takeuchi
  1. Metabolic Disease Drug Discovery Unit (Y.T., R.I., M.S., A.H., K.T.), Inflammation Drug Discovery Unit (N.N.), and Project Management Office (Y.M.), Pharmaceutical Research Division, and Chemical Development Laboratories, CMC Center (T.Y.), Takeda Pharmaceutical Company Limited, Osaka, Japan
  1. Address correspondence to:
    Dr. Yoshiyuki Tsujihata, Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan. E-mail: tsujihata_yoshiyuki{at}takeda.co.jp
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: July 2011 to April 2021

AbstractFullPdf
Jul 20112960285
Aug 20111730323
Sep 201137245318
Oct 201144896241
Nov 201117570165
Dec 201114369152
Jan 201215744133
Feb 201216052164
Mar 201220371174
Apr 201215054117
May 201211654130
Jun 201212457152
Jul 20129724134
Aug 201213230104
Sep 2012743493
Oct 20127874136
Nov 20129095179
Dec 20125958155
Jan 20138580209
Feb 20137978146
Mar 20138685181
Apr 20136690168
May 201368109179
Jun 20136381157
Jul 201372101152
Aug 20135081111
Sep 2013105107173
Oct 201359123154
Nov 20136599126
Dec 201354113126
Jan 20144290108
Feb 20143970102
Mar 20143563118
Apr 2014336477
May 2014353665
Jun 2014304060
Jul 2014525956
Aug 2014645255
Sep 2014275085
Oct 2014394750
Nov 2014312441
Dec 2014322552
Jan 2015243037
Feb 2015322023
Mar 2015354647
Apr 2015183246
May 2015274550
Jun 201595160
Jul 2015125837
Aug 2015143431
Sep 2015183131
Oct 2015273431
Nov 2015194750
Dec 2015364666
Jan 2016194541
Feb 2016133242
Mar 2016203136
Apr 2016104025
May 2016134142
Jun 2016293928
Jul 2016264646
Aug 2016273938
Sep 2016413546
Oct 201693920
Nov 2016206350
Dec 201652521
Jan 201762923
Feb 201731912
Mar 201782616
Apr 201751912
May 201763529
Jun 2017143425
Jul 201763028
Aug 201742827
Sep 201732524
Oct 201772321
Nov 201773624
Dec 201744326
Jan 2018113832
Feb 201863021
Mar 201841925
Apr 201822615
May 201843823
Jun 201802510
Jul 201833320
Aug 201833816
Sep 2018132724
Oct 201811117
Nov 201831314
Dec 20182988
Jan 201941414
Feb 20191510
Mar 20192041
Apr 20191724
May 201928815
Jun 201914111
Jul 201941411
Aug 201924510
Sep 20193946
Oct 20192866
Nov 20193466
Dec 20195269
Jan 20201817
Feb 202032412
Mar 20206637
Apr 20205257
May 20202136
Jun 20203755
Jul 20202011
Aug 20201707
Sep 20201643
Oct 20202625
Nov 202032311
Dec 20203548
Jan 2021361714
Feb 2021481725
Mar 202148711
Apr 20214304

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 339 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 339, Issue 1
1 Oct 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleEndocrine and Diabetes

GPR40 Agonist as a Potential Antidiabetic Drug

Yoshiyuki Tsujihata, Ryo Ito, Masami Suzuki, Ayako Harada, Nobuyuki Negoro, Tsuneo Yasuma, Yu Momose and Koji Takeuchi
Journal of Pharmacology and Experimental Therapeutics October 1, 2011, 339 (1) 228-237; DOI: https://doi.org/10.1124/jpet.111.183772

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleEndocrine and Diabetes

GPR40 Agonist as a Potential Antidiabetic Drug

Yoshiyuki Tsujihata, Ryo Ito, Masami Suzuki, Ayako Harada, Nobuyuki Negoro, Tsuneo Yasuma, Yu Momose and Koji Takeuchi
Journal of Pharmacology and Experimental Therapeutics October 1, 2011, 339 (1) 228-237; DOI: https://doi.org/10.1124/jpet.111.183772
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Ginsenoside Ro ameliorates obesity via TGR5 pathway
  • A Novel Polymeric Sequestrant Delays Diabetic Nephropathy
  • NMDA Receptor Antagonists and β-Cells
Show more Endocrine and Diabetes

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics